MONTREAL, Canada, June 12 /CNW Telbec/ - Technologie Biolactis, Inc., a
Canadian biotechnology company specializing in the development of
lactoceuticals focused on cardiovascular, metabolism and obesity-associated
disorders, is pleased to announce the appointment of Mr. Wolfgang
Reichenberger, Ph.D., to its Board of Directors.
    "It is with great enthusiasm that we welcome Dr. Reichenberger on the
Board of Biolactis. His extensive global market and financing experience will
greatly benefit Biolactis," said Pierre Lemieux, Ph.D., chairman of the board
of Directors and President and CEO of Biolactis. "Dr. Reichenberger's
successful track record of managing Companies and divisions in Food and
Beverages, including the development and launches of products, in Europe, the
United States, Oceania and Asia, represents an important resource to Biolactis
as the Company is advancing its pipeline through clinical trials" added
Dr. Lemieux.  His close to thirty years global experience will be very
valuable in bringing alternative perspectives to the Company's management team
through the Board, as well as in elaborating strategies to enable sustainable
growth.
    "I am pleased to join the Board of Biolactis. Obesity and metabolic
syndrome represent a therapeutic area of major interest for Inventages and
novel approaches with new mechanism of action are highly in demand around the
globe. Biolactis's unique products, which are based on novel synergistic
mechanisms of action, will bridge the gap between the food and pharmaceutical
industry, addressing effective prevention and management of chronic life style
related conditions, like hyperlipidemia, obesity, and diabetes", affirmed
Mr. Reichenberger.

    Mr. Reichenberger

    He joined Nestlé, the world's largest Food and Beverage Company almost
30 years ago in his native Austria, and grew through management positions in
Brazil, the United States, Switzerland, the Philippines, New Zealand and
Japan, culminating in five years as global CFO, 2001-2005. He believes that
breakthrough innovation are increasingly coming from start-up Companies, in an
entrepreneurial business model. He therefore joined recently Inventages, and
co-founded W.Health, the Growth Fund of EUR 750 millions, investing in
start-up and buy-out Companies in the field of Health, Wellbeing and
Nutrition, sponsored by Nestle.

    Biolactis

    Biolactis, Inc. is a privately held, Canadian-based biotechnology company
focused on developing novel bioactive ingredients, nutraceuticals and medical
food, addressing obesity and metabolic syndrome-associated problems. For
further information, please visit www.biolactis.com and www.nutractis.com

    Inventages Investment Capital Inc.

    Inventages Venture Capital is a fund management company specializing in
life sciences, with business offices in the Bahamas, Switzerland and New
Zealand. It currently manages five funds, and has more than EUR 1 billion
under management. The funds have a strong focus on prevention and nutrition.
The limited partners are mainly strategic investors. Inventages concentrates
on selective investments in the field of disease prevention and chronic
disease management. Portfolio companies are intensively supported and can
leverage the deep business experiences and strong relationships of the
Inventages' partners within the global pharmaceutical, cosmetics, food and
biotech industries. For further information please visit www.inventages.com.